Haleon (HLN) Stock Forecast & Price Target

GBX 380.60 -0.50 (-0.13%)

(As of 11:52 AM ET)

Haleon - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
0

Buy
3

Based on 3 Wall Street analysts who have issued ratings for Haleon in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for HLN.

Consensus Price Target

GBX 415

According to the 3 analysts' twelve-month price targets for Haleon, the average price target is GBX 415. The highest price target for HLN is GBX 447, while the lowest price target for HLN is GBX 383. The average price target represents a forecasted upside of 9.04% from the current price of GBX 380.60.

Get the Latest News and Ratings for HLN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Haleon and its competitors.

HLN Analyst Ratings Over Time

Type	Current Forecast 12/24/23 to 12/23/24	1 Month Ago 11/24/23 to 11/23/24	3 Months Ago 9/25/23 to 9/24/24	1 Year Ago 12/24/22 to 12/24/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	GBX 415	GBX 415	GBX 367.50	GBX 351.71
Consensus Rating	Buy	Buy	Moderate Buy	Hold

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

HLN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HLN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Haleon Stock vs. The Competition

Type	Haleon	Medical Companies
Consensus Rating Score	3.00	2.81
Consensus Rating	Buy	Moderate Buy
News Sentiment Rating	Neutral News See Recent HLN News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
8/5/2024	Berenberg Bank 2 of 5 stars	Boost Target	Buy	GBX 410 ➝ GBX 447	+23.60%
4/18/2024	HSBC 3 of 5 stars	Initiated Coverage	Buy
4/9/2024	Barclays 3 of 5 stars	Lower Target	Overweight	GBX 390 ➝ GBX 383	+19.28%
10/11/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		GBX 340 ➝ GBX 360	+6.82%
10/10/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight	GBX 280	-17.59%
8/9/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		GBX 390 ➝ GBX 387	+18.99%
8/9/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		GBX 375 ➝ GBX 370	+13.76%
3/7/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		GBX 358 ➝ GBX 344	+7.15%
3/6/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Hold	GBX 335 ➝ GBX 330	+4.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:30 PM ET.

Should I Buy Haleon Stock? HLN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 18, 2024. Please send any questions or comments about these Haleon pros and cons to contact@marketbeat.com.

Haleon
Bull Case

Here are some ways that investors could benefit from investing in Haleon plc:

Haleon plc is largely controlled by institutional shareholders, who own 72% of the company, indicating strong backing and confidence from major investors.
The company has a diverse portfolio of well-known consumer healthcare brands, including Sensodyne and Centrum, which can provide stability and growth potential in the consumer goods market.
Recent developments in the healthcare sector have increased demand for over-the-counter products, which Haleon offers under brands like Voltaren and Theraflu, positioning the company well for revenue growth.
The current stock price of Haleon plc reflects its market position and investor sentiment, making it an attractive option for those looking to invest in a stable company within the drug manufacturing industry.
Haleon plc's long history, founded in 1715, suggests a strong legacy and experience in the market, which can be appealing to investors looking for established companies.

Haleon
Bear Case

Investors should be bearish about investing in Haleon plc for these reasons:

Despite its strong brand portfolio, Haleon plc operates in a highly competitive market, which can pressure profit margins and market share.
The reliance on institutional shareholders may lead to volatility in stock performance, as large investors can influence stock prices significantly.
Changes in consumer preferences and regulatory challenges in the healthcare sector could impact the sales of Haleon's products, posing risks to revenue stability.
Economic downturns can affect consumer spending on healthcare products, which may lead to decreased sales for Haleon plc.
Investors may find the company's growth potential limited compared to more innovative firms in the pharmaceutical sector, which could affect long-term investment returns.

HLN Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Haleon is GBX 415, with a high forecast of GBX 447 and a low forecast of GBX 383.
: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haleon in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HLN shares.
: According to analysts, Haleon's stock has a predicted upside of 9.04% based on their 12-month stock forecasts.
: Analysts like Haleon more than other "medical" companies. The consensus rating for Haleon is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

This page (LON:HLN) was last updated on 12/23/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haleon (HLN) Stock Forecast & Price Target